Topical Lingual PYY

About Gila Therapeutics

Gila Therapeutics is a San Diego-based biotech founded in 2018, targeting the massive obesity and cardiometabolic market with a first-of-its-kind neural signaling platform. The company's core technology involves topical lingual administration of peptides (e.g., PYY, GLP-1) to activate the brain's metabolic control centers via oral receptors, aiming to bypass systemic side effects like nausea. Having completed a successful Phase I trial with no treatment-related adverse events, Gila is advancing its pipeline through strategic partnerships and is positioned as a potential disruptor in the incretin therapy space by offering a non-systemic, convenient treatment modality.

Therapeutic Areas

Other Obesity / Cardiometabolic Disorders Drugs